Advances in Clinical and Experimental Medicine

Advances in Clinical and Experimental Medicine 5-Year IF 2.0, IF 1.9, JCI (2024) 0.43, Scopus CiteScore 4.3, H-index 49 (SJR)
Initial editorial assessment and first decision within 24 h

📢14th EURIPA Rural Health Forum📢Rural Reformation: Meeting Wellbeing and Healthcare Needs in Rural Communities26–28 June...
26/06/2025

📢14th EURIPA Rural Health Forum📢
Rural Reformation: Meeting Wellbeing and Healthcare Needs in Rural Communities

26–28 June 2025
Wittenberg, Saxony-Anhalt, Germany

European Rural and Isolated Practitioners Association (EURIPA) is a representative network organisation founded by family doctors to address the health and wellbeing needs of rural communities and the professional needs of those serving them across Europe. It represents a growing network of rural practitioners and organisations across Europe working together to disseminate good practice, initiate research and influence policy.

https://www.euripa.org/m/events/view/14th-euripa-rural-health-forum

THE ABSTRACT BOOK OF THE MEETING:
https://ojs.umw.edu.pl/files/acem/EURIPA-2025-cale-3.pdf


Donata Kurpas

📢New Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection onRevolutionizing Canc...
25/06/2025

📢New Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection on

Revolutionizing Cancer Treatment: Navigating the Intricate Landscape of Cellular Signaling Networks📢

Handling Editors
Prof. Hao Zhang (Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University) [[email protected]].

Outline
Cancer arises from disruptions in the intricate cell signaling networks that drive tumor cell behavior. Chemotherapy and immunotherapy are the main cancer treatment approaches, but the complexity of these signaling networks often hinders the success of targeted therapies. Understanding the cell signaling networks involved in cancer development and progression is crucial. Challenges like drug resistance and metastasis underscore the need for novel approaches targeting key signaling networks for more effective cancer treatment.
Immunotherapy has shown promise by stimulating the patient's immune system but only benefits a subset of patients. Current research has identified many signaling pathways influencing cancer cell growth, spread, and drug resistance. However, the complexity of these signaling networks limits the successful clinical application of individual molecular targets. An in-depth understanding of the functions and regulation of key signaling networks associated with tumor progression is essential to develop new chemotherapies and targeted treatments.

This research initiative seeks submissions on topics like:
1. Immune regulatory networks influencing cancer progression and prognosis
2. Signaling pathways involved in cancer initiation and metastasis
3. Biomarkers for predicting responses to immunotherapy and chemotherapy
4. Crucial cell signaling networks governing immune responses
5. Using multi-omics to reveal critical cancer signaling networks

Keywords
signaling networks, cancer treatment, biomarker, immune response, immunotherapy, multi-omics, cancer progression and prognosis

Submission process
As a first step, we ask for submissions of an Expression of Interest with an Abstract of original papers outlining the themes above to Adv Clin Exp Med Managing Editor Marek Misiak [[email protected]].
The Editor-in-Chief will review all submissions and select those invited to submit a full paper. The submission process will follow the regular Adv Clin Exp Med online process. All manuscripts will be sent to at least two independent reviewers.

Dates and fees
Submission of Expression of Interest until December 31, 2024, to the ACEM Managing Editor: [email protected];
Invitation to submit the full paper by January 31, 2025;
Submission of full paper by December 31, 2025.

If the paper is accepted, Authors will be required to pay a fee to cover publication costs (https://advances.umw.edu.pl/en/article-processing-charges/). For selected Authors (outstanding experts), reducing or even cancelling the publication fee is possible.

By submitting your research to Adv Clin Exp Med, you will become an integral part of a dynamic and vibrant community of dedicated researchers committed to advancing the fields of clinical and experimental medicine. By undergoing our rigorous peer-review process, you can be assured that only high-quality and impactful studies are published, enhancing your professional reputation and contributing to advancing medical knowledge.
We look forward to receiving your submissions and collaborating to make a lasting impact on the field of clinical and experimental medicine!

https://advances.umw.edu.pl/en/revolutionizing-cancer-treatment

📢MEETING WITH A STATISTICIAN – HOW TO USE STATISTICS IN A SCIENTIFIC ARTICLE?📢✔️WHEN?June 25, 20259:00 CET✔️WHERE?MS Tea...
25/06/2025

📢MEETING WITH A STATISTICIAN – HOW TO USE STATISTICS IN A SCIENTIFIC ARTICLE?📢

✔️WHEN?
June 25, 2025
9:00 CET

✔️WHERE?
MS Teams platform
https://teams.microsoft.com/l/meetup-join/19%3ameeting_NWZlZmM4ZjYtNmZjOC00NWUwLTliZWUtYzc3ZDYyZDIxMjBk%40thread.v2/0?context=%7b%22Tid%22%3a%22c49499a2-f68e-48a6-8885-7b5d4eaa01a3%22%2c%22Oid%22%3a%22d52777a9-074a-4926-8ad2-7fd34b593398%22%7d

✔️ Dr. Krzysztof Kujawa, head of the Centre for Statistical Analysis at Wroclaw Medical University, will share essential insights on:
• how to avoid common statistical pitfalls,
• what editors look for in methodology sections,
• and why sound stats = higher acceptance rates.

Bring your questions! The session is open to everyone, especially researchers in medicine, pharmacy & health sciences.

It is worth noting that the rules discussed are not specific only to our journal – many scientific journals use some form of verification of the statistical methods used in the submitted papers. At the meeting, you will be able to discuss this with our expert.

Link to the journal website:

https://advances.umw.edu.pl/en/home

You are cordially invited - everyone is welcome. If you have any questions, I remain at your disposal.

--
Marek Misiak, MA [pronouns: he, his, him]
English-Language Publications Editor, Managing Editor
Advances in Clinical and Experimental Medicine
Polimery w Medycynie – Polymers in Medicine
Wroclaw Medical University Press
ul. K. Marcinkowskiego 2–6, 50-368 Wrocław
phone: +48 71 784 12 05
mobile phone: +48 607 983 232
https://advances.umw.edu.pl/
https://polimery.umw.edu.pl/
https://wydawnictwo.umw.edu.pl/en/home/

Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

📢Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection onApplication of stem cell...
24/06/2025

📢Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection on

Application of stem cells in human medicine – from basic science research to clinical trials 📢

Medicine in the twenty-first century is closely associated with stem cell research, based on advanced in vitro analyzes, the use of model animals, and their application in clinical trials. Experimental research requires understanding the physiological and morphological properties of stem cells and analyzing their ability to divide and differentiate into other cell types. The best-known stem cells are those derived from bone marrow and umbilical cord blood. However, in recent years, stem cells have been discovered in, for example, adipose tissue and Wharton jelly. Stem cells isolated from these tissues, once properly differentiated, are increasingly used for the treatment of bone and neurodegenerative diseases. In recent years, the number of therapies using stem cells has increased significantly. The ability of stem cells to differentiate makes them an increasingly common therapeutic tool in regenerative and reconstructive medicine.

Key words:

mesenchymal stem cells, embryonic stem cells, iPSCs, cancer stem cells, cell proliferation and differentiation, small extracellular vesicles, exosomes, omics, animal models, preclinical and clinical trials, regenerative medicine, reconstructive medicine

Articles submitted should be related to the topic of stem cells and their use in basic and clinical research. Topics may include:

• molecular research involving advanced genomic methods
• tissue and cell research
• studies on the morphological and physiological properties of stem cells
• studies on the proliferative and multidirectional differentiation capacity of stem cells
• studies on model animals
• use of stem cells in preclinical and clinical research
• therapies with stem cell
• stem cells in regenerative and reconstructive medicine
• stem cells in translational medicine

Review articles describing recent achievements in stem cell medicine, as well as original articles will be accepted.

MORE INFORMATION:

https://advances.umw.edu.pl/en/application-stem

📢Thank you for your contribution to the success of Advances in Clinical and Experimental Medicine!📢We are pleased to sha...
23/06/2025

📢Thank you for your contribution to the success of Advances in Clinical and Experimental Medicine!📢

We are pleased to share that, while the Impact Factor of Advances in Clinical and Experimental Medicine has remained at a comparable level to the previous year (5-Year Impact Factor has not changed – 2.0), CiteScore and other Scopus-based metrics have shown growth (from 3.7 for 2023 to 4.3 in 2024), reflecting the consistent strength and influence of the research we publish.

In a time when many journals face challenges with volatility in scientometric indicators, our ability to maintain a stable and high level of quality is a success in itself. This achievement underscores the robustness of our editorial processes and the relevance of the work we collectively advance.

We would like to express our deepest appreciation to all Authors, Reviewers, Section Editors, Scientific Committee members, and WMU Press for their exceptional commitment, expertise, and collaboration. Your contributions not only sustain the scientific integrity of the journal, but also drive forward its reputation and reach.

Together, we continue to build a journal that upholds academic excellence and delivers meaningful impact on clinical and experimental medicine. Thank you for being an integral part of this ongoing success.

Warm regards,
The Editorial Team
Advances in Clinical and Experimental Medicine

Types of articles in Advances in Clinical and Experimental Medicine in 2021 and 2022: Editors’ perspectiveThe present ed...
22/06/2025

Types of articles in Advances in Clinical and Experimental Medicine in 2021 and 2022: Editors’ perspective

The present editorial summarizes the last 2 calendar years of Advances in Clinical and Experimental Medicine (ACEM) publication (2021 and 2022). The specific aims were: 1) To clarify the classification of papers published in ACEM; 2) To present motivations behind choosing this classification; 3) To show how this classification is reflected in citations. Six categories of papers published in ACEM are presented: editorials, meta-analyses, reviews (including systematic reviews), multicenter studies, research-in-progress studies, and research letters; lack of clear definitions for editorials, research letters and research-in-progress studies is discussed. Thematic fields covered by all categories in 2021 and 2022 are presented and differences in this regard between 2021 and 2022 are highlighted. Reasons for not publishing case reports (CRs) are discussed, with some of the debate on this issue in medical literature summarized. The article type classification used in ACEM in only one of many possible solutions and may be modified in the future – it should be both clear for the authors and allow for orientation in the journal’s content. The motivation for choosing the employed categories stem both from their position on the accepted levels of evidence in evidence-based medicine (EBM) and their potential to be cited.

https://advances.umw.edu.pl/en/ahead-of-print/176003/

📢 Our new manuscript withdrawal policy 📢✔️ Withdrawals initiated by authorsAuthors may withdraw their manuscript at any ...
21/06/2025

📢 Our new manuscript withdrawal policy 📢

✔️ Withdrawals initiated by authors
Authors may withdraw their manuscript at any stage of the editorial process. However, 2 conditions must be met for a withdrawal request to be processed:

– A clear and specific reason for withdrawal must be provided – both in the Editorial System and in the withdrawal statement.
– All authors must consent to the withdrawal. A statement signed by all authors should be scanned and submitted as a PDF file to the editorial office at [[email protected]] and/or uploaded to the Editorial System as an Additional File.

Until these conditions are fulfilled, the manuscript cannot be considered withdrawn.

Please note that if you intend to resubmit the manuscript, it is advisable to address necessary corrections during the initial verification or peer-review process rather than withdrawing the submission. A withdrawn and resubmitted manuscript is assessed as an entirely new submission – the previous (withdrawn) submission is not taken into consideration; in consequence, it prolongs the whole assessment process.

✔️ Withdrawals initiated by the editorial office
A manuscript will be withdrawn by the editorial office if:

– After acceptance, evidence for scientific misconduct is found
– Authors fail to sign the license agreement form within 30 days after acceptance
– Authors fail to pay the article processing charge (APC) within 30 days after acceptance
– Authors repeatedly fail to correct the galley proof or cease communication with the editorial office in this regard for more than 30 days.

✔️ Refund policy (withdrawals after the APC has already been paid)
Adv Clin Exp Med does not refund the APC once it has been paid. This policy applies in the following cases:
– When authors withdraw a manuscript after acceptance and payment of the APC (but before publication), regardless of the reason for withdrawal.
– When the manuscript is withdrawn by the editors due to the authors' failure to adequately correct errors or an attempt to change the authorship after acceptance (which violates our policy).
– When articles are retracted after publication due to author error or misconduct.
The APC is not a publication fee but an article-processing charge—it covers the costs of peer review, statistical review, editing, and typesetting. Since the majority of this work is completed before the APC is paid, refunds cannot be issued.
In exceptional cases, authors may appeal to the Editor-in-Chief, whose decision is final.

✔️ Withdrawal after acceptance due to funding limitations
We ask that authors submit papers to our journal only if they have funding. Before submitting, please make sure that you have the necessary funds to pay the APC in case of acceptance.
https://advances.umw.edu.pl/en/article-processing-charges/
Please note that our journal offers neither APC waivers nor discounts, including discounts for researchers from lower-income countries and countries against which international sanctions have been imposed.

✔️ Ethical considerations concerning withdrawals
Before you withdraw a paper, please consider that the editor and reviewers have likely already invested significant time reviewing your manuscript. The further along in the paper's peer-review process, the greater the ethical concern with withdrawing a manuscript, given that a considerable amount of time has been spent on the paper by reviewers, editors, and editorial assistants. Please let us know before withdrawing if there is anything we can do to avoid the withdrawal. We are happy to work with authors to remove any perceived barriers to publishing.
Please note that it is unethical and considered violating scientific norms (i.e., poor scientific practice bordering on scientific misconduct) to submit a paper still under consideration at a journal A to a different journal B. If you have already created a duplicate submission, please withdraw your paper from the other journal immediately and only submit it after receiving confirmation that your withdrawal request has been successfully processed. Otherwise, according to international best practices on publication ethics, a withdrawal may violate the research community's norms and may have negative consequences for the authors.

✔️ Withdrawing a published paper
Withdrawal is possible during the initial verification process, from the peer-review process or after acceptance, before publication. Withdrawing a paper after publication is called a retraction, please see https://advances.umw.edu.pl/en/appeals-complaints-corrections-retractions-commentaries for retraction policies.

📢Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection on Advances in Cardiovascu...
21/06/2025

📢Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection on Advances in Cardiovascular Care 📢

This Special Issue of the Advances in Clinical and Experimental Medicine will provide focused, comprehensive coverage of important clinical topics in cardiology. The issue will address selected clinical problems or conditions, including their pathophysiology, invasive and noninvasive diagnosis, drug therapy, surgical management, and rehabilitation.

This Special Issue aims to provide researchers with an opportunity to publish original research, meta-analyses and review articles related to recent advances in the cardiovascular field, with a particular focus on holistic and personalized management of patients with CVD.

Topic and format
Advances in Clinical and Experimental Medicine is therefore seeking original papers for a Special Collection focused on cardiovascular care.

MORE INFORMATION:

https://advances.umw.edu.pl/en/call-for-submissions-of-an-expression-of-interest-for-an-adv-clin-exp-med-special-collection-on-advances-in-cardiovascular-care


Izabella Uchmanowicz
Dr hab. Michał Czapla
Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

🧬 Two drugs, one mission: killing cancer cells In chronic lymphocytic leukemia (CLL), malignant cells escape apoptosis—t...
20/06/2025

🧬 Two drugs, one mission: killing cancer cells

In chronic lymphocytic leukemia (CLL), malignant cells escape apoptosis—the body's natural self-destruct system. As a result, they accumulate and take over the blood, lymph nodes, and bone marrow.

But scientists from Łódź, Wrocław, and Rzeszów may have found a way to restore that lost balance.

Their study, published in Advances in Clinical and Experimental Medicine, shows that venetoclax, a modern targeted drug, and cladribine, a classic chemotherapy agent, work better together than alone. The combo strongly activated pro-death genes and reawakened multiple apoptotic pathways—even in patients with poor prognostic markers.

💡 Though tested in the lab, the findings open new possibilities for more effective therapies—especially in cases where standard treatment fails.

📖 Read more: https://advances.umw.edu.pl/en/ahead-of-print/199382/

🔊 Listen: https://soundcloud.com/wmu-pl/combination-therapies-two-drugs-one-goal-killing-cancer-cells?utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing&si=67a5fc019bfa41b2b34c4844d6083abe

🏳️‍🌈 In celebration of Pride MonthOur journal Advances in Clinical and Experimental Medicine is currently accepting subm...
19/06/2025

🏳️‍🌈 In celebration of Pride Month

Our journal Advances in Clinical and Experimental Medicine is currently accepting submissions on LGBTQ+ health and equity.

Science doesn’t exclude - it explores.

Join the conversation:

🔗 https://advances.umw.edu.pl/en/lgbt

📚
Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

🚀Ahead of print🚀🚀An underrated clinical tool: CBC-derived inflammation indices as a highly sensitive measure of systemic...
18/06/2025

🚀Ahead of print🚀

🚀An underrated clinical tool: CBC-derived inflammation indices as a highly sensitive measure of systemic immune response and inflammation🚀

Highlights

• CBC-DIIs offer a sensitive and low-cost measure of systemic immune activation and suppression.
• The correlation of indices like SII, SIRI, and AISI extends beyond disease severity in cancer, cardiovascular, autoimmune, and neuropsychiatric conditions.
• CBC-DIIs demonstrate clinical utility in depression, trauma, periodontitis, diabetic complications, and other diseases and conditions.
• Current indices rely on linear algebraic expressions, which limit their specificity in complex or chronic disease states with an inflammatory background.
• Creating nonlinear CBC-DIIs equations and integrating these with genomic, imaging, and nonlinear computational models may enhance personalized diagnostics.

https://advances.umw.edu.pl/en/ahead-of-print/205833/



Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
Victor Geller

Adres

Karola Marcinkowskiego 2-6
Wroclaw
50-368

Godziny Otwarcia

Poniedziałek 08:00 - 16:00
Wtorek 08:00 - 16:00
Środa 08:00 - 16:00
Czwartek 08:00 - 16:00
Piątek 08:00 - 16:00

Telefon

+48607983232

Ostrzeżenia

Bądź na bieżąco i daj nam wysłać e-mail, gdy Advances in Clinical and Experimental Medicine umieści wiadomości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu i możesz zrezygnować z subskrypcji w dowolnym momencie.

Skontaktuj Się Z Firmę

Wyślij wiadomość do Advances in Clinical and Experimental Medicine:

Udostępnij

Kategoria